The CDMO Codis has announced it will acquire Catalent Pharma Solutions' (Catalent) spray-drying facility in Nottingham, UK.
The purchase will add oral solid dose (OSD) development and small-scale manufacturing capabilities and create Europe's leading single-partner path for integrated spray-dry solutions, from development through clinical supply and commercial intermediates to final oral dose forms.
It is expected to close in Q3 of this year, subject to customary closing conditions.
The Nottingham site features a team with significant expertise in formulation development and clinical supply, delivering spray drying and OSD solutions for more than 20 years.
Codis said in its statement that the acquisition will enhance its large-scale commercial spray-drying facility in Haverhill, UK, which is expanding with a new GEA Pharma-SD-type PSD-4 dryer, set for validation in 2027.
It will also strengthen the firm's portfolio for bioavailability enhancement by offering integrated development, analytical services and clinical and small-scale commercial manufacturing.
"This strategic acquisition will further establish Codis as a leading European provider of comprehensive spray-dry solutions," said Nicolas Fortin, CEO of Codis.
The close proximity of our Nottingham and Haverhill sites creates a unique advantage. Codis can now offer access to the best scientific expertise with a strong, integrated manufacturing capability within a single organisation and quality system.
He added: "Most small-molecule drug candidates suffer from poor solubility and spray-dried dispersions have become one of the primary approaches to improving bioavailability. Yet one of the greatest development risks remains the transfer from formulation to commercial-scale manufacturing."
By bringing formulation development and GMP manufacturing together, we provide the fastest, lowest-risk path to unlocking a molecule's full potential.
